The assumption that thyroid hormone replacement is a lifelong commitment may be more assumption than fact — at least for a meaningful subset of older adults. Evidence emerging from a structured deprescribing trial is prompting clinicians to reconsider whether continuing levothyroxine indefinitely serves all aging patients, or whether some were prescribed it under circumstances that no longer apply.
A deprescribing protocol evaluated by Ravensberg and colleagues demonstrated that a substantial proportion of older adults can successfully discontinue levothyroxine without adverse thyroid outcomes. This challenges the entrenched clinical default of indefinite thyroid hormone therapy. A subsequent clinical commentary published in JAMA added nuance by examining what "unsuccessful discontinuation" actually means — noting that failure to discontinue is not a uniform outcome and may reflect distinct physiological subgroups rather than a single binary result. The commentary underscores that interpreting deprescribing trial data requires careful attention to how endpoints are defined and how patient heterogeneity is handled.
This matters within a broader pharmacological context. Levothyroxine is among the most prescribed medications globally, particularly in adults over 65, where subclinical hypothyroidism is frequently diagnosed and treated despite ongoing debate about whether treatment improves clinical outcomes in this age group. Landmark trials such as the TRUST study previously found that levothyroxine provided no measurable quality-of-life benefit in older adults with mild subclinical hypothyroidism, raising questions about widespread prescribing. The deprescribing framework adds a logical next step: if initiation is often questionable, systematic re-evaluation of existing prescriptions is clinically justified. Key limitations include the need for larger randomized trials across diverse populations, longer follow-up periods to capture delayed thyroid dysfunction, and clearer stratification by original diagnosis. As a body of evidence, this remains incremental but clinically meaningful — especially for practitioners navigating polypharmacy in aging patients.